Dr. Reddy's Laboratories launches Tobramycin Inhalation Solution, USP in US market

Dr. Reddy's Laboratories announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration.

The TOBI (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health.

Dr. Reddy's Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule.

Tobi is a trademark of Mylan.

Powered by Capital Market - Live News